CSIMarket
 
Olink Holding Ab publ   (OLK)
Other Ticker:  
 
 
Price: $22.2900 $-0.37 -1.633%
Day's High: $22.97 Week Perf: -3.21 %
Day's Low: $ 22.21 30 Day Perf: -6.93 %
Volume (M): 646 52 Wk High: $ 26.01
Volume (M$): $ 14,406 52 Wk Avg: $21.29
Open: $22.59 52 Wk Low: $14.10



 Market Capitalization (Millions $) 2,817
 Shares Outstanding (Millions) 126
 Employees 267
 Revenues (TTM) (Millions $) 169
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 19

Olink Holding Ab Publ
Olink Holding AB publ is a publicly traded life science company based in Uppsala, Sweden.
The company specializes in developing high-quality protein analysis technology that enables researchers and clinicians to analyze proteomic data within complex biological samples in a reliable and efficient manner.
The company's patented technology, known as Proximity Extension Assay (PEA), allows for the measurement of large numbers of proteins in small sample volumes, with high sensitivity and specificity.
Olink's technology is primarily used by researchers in the fields of biomarker discovery, drug development, and clinical diagnostics.
The company's products include a range of panels of validated biomarker assays, which can be used to measure protein biomarkers in various disease areas, including cancer, cardiovascular disease, and inflammation.
Olink was founded in 2004 and has since grown to become a leading provider of cutting-edge protein biomarker analysis technology.
The company is publicly traded on the Nasdaq Stockholm exchange under the ticker symbol OLK.

The company's mission is to enable precision medicine by providing researchers and doctors with the tools they need to develop better treatments and diagnostic tests for a wide range of diseases.


   Company Address: Salagatan 16F Uppsala 75330 MA
   Company Phone Number: 393-3933   Stock Exchange / Ticker: NASDAQ OLK
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Olink Insight Unveils Open-access Map of the Human Proteome, Aiding Biomarker Discovery and Understanding of Disease

Published Tue, Apr 2 2024 12:01 PM UTC

Olink Insight, a leading innovator in precision proteomics, has recently announced the launch of a groundbreaking open-access data library. This library comprises more than 300,000 protein-disease risk associations across 106 human diseases, providing a valuable resource for researchers and scientists. The availability of this unprecedented information is poised to catalyze ...

Olink Holding Ab Publ

Financial Growth and Strategic Partnerships Drive Olink Holding Ab Publ's Expansion

Investors in the Laboratory Analytical Instruments sector may be pleased to hear that Olink Holding Ab Publ has announced a significant surge in revenue for the October to December 31, 2023 interval. The company reported a 21.175% increase in revenue to $169.46 million compared to the same period the year before.
Despite the revenue growth, Olink Holding Ab Publ also reported an increased deficit per share at $-0.25 per share, compared to $-0.11 in the previous fiscal year. This widening deficit may cause concern for some investors, especially as many of the company's industry peers have experienced business reductions during the same period.
It is important to note that Olink Holding Ab Publ is expected to report its next financial numbers on March 26, 2024, which may provide further insight into the company's performance and future outlook.
In addition to its financial results, Olink Holding Ab Publ has recently announced a partnership with Novogene Asia Pacific Middle East and Africa (AMEA) to propel multi-omics research to new heights. Leveraging cutting-edge technology, this partnership aims to advance personalized medicine and precision therapies by unraveling the connections between genes, proteins, and diseases.

Contract

Revolutionizing Multi-Omics Research: Novogene AMEA Unleashes the Power of Olink Explore HT for Unraveling the Secrets of Genes, Proteins, and Diseases

Published Mon, Nov 6 2023 1:00 AM UTC


Novogene Asia Pacific Middle East and Africa (AMEA) has recently announced its groundbreaking partnership with Olink to propel multi-omics research to new heights. Leveraging the cutting-edge Olink Explore HT high-throughput proteomics technology, Novogene AMEA aims to unravel the intricate connections between genes, proteins, and diseases, paving the way for groundbrea...






 

Olink Holding Ab Publ's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Olink Holding Ab Publ does not provide revenue guidance.

Earnings Outlook
Olink Holding Ab publ does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com